Please login to the form below

Not currently logged in
Email:
Password:

Heart drug

This page shows the latest Heart drug news and features for those working in and with pharma, biotech and healthcare.

Novartis’ heart failure drug Entresto proves superior to enalapril

Novartis’ heart failure drug Entresto proves superior to enalapril

Novartis’ heart failure drug Entresto proves superior to enalapril. Results could see the drug strengthen its position in the market. ... Novartis has released new data for its heart failure treatment Entresto which could help convince doctors and

Latest news

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    The data reveals that the drug was better than two-drug combinations in preventing COPD exacerbations, reducing attacks by 52% compared to AZ’s LAMA/LABA combination Bevespi (glycopyrronium/formoterol fumarate). ... As the two drug combinations are at

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    The drug was approved to treat chronic heart failure patients with reduced ejection fraction (HFrEF) or systolic dysfunction in 2015 and - after a sluggish start - finally seems to be developing sales ... There wasn’t much to report on in terms of new

  • Amgen gets prevention claim for cholesterol drug Repatha Amgen gets prevention claim for cholesterol drug Repatha

    Amgen gets prevention claim for cholesterol drug Repatha. FDA approves new labelling on heart attack and stroke risk reduction. ... The US FDA has approved new labelling saying that Amgen’s cholesterol drug Repatha can reduce the risk of heart attacks

  • Vas Narasimhan takes top Novartis job on Jimenez departure Vas Narasimhan takes top Novartis job on Jimenez departure

    Harvard -trained physician Narasimhan has been with Novartis since 2005 and has held a number of roles at the company across commercial, drug development and strategy but is "deeply anchored in ... showed an uptick in performance but remains under

  • Alcon's return to growth gives Novartis 'options', says CEO Alcon's return to growth gives Novartis 'options', says CEO

    Immunotherapy Cosentyx (secukinumab) for psoriasis, ankylosing spondylitis and psoriatic arthritis rocketed 90% to reach $490m in the quarter, while slow-burner Entresto (sacubitril and valsartan) for heart failure contributed $110m and ... A string of

More from news
Approximately 1 fully matching, plus 180 partially matching documents found.

Latest Intelligence

  • Transforming Access to Medicines Through Patient-Centric Solutions Transforming Access to Medicines Through Patient-Centric Solutions

    to medicines and the importance of putting patients at the heart of drug development and access. ... Patients at the heart of drug development and access. If you believe the news every day, patients are becoming more and more involved in drug development

  • Transforming Access to Medicines Through Patient-Centric Solutions Transforming Access to Medicines Through Patient-Centric Solutions

    to medicines and the importance of putting patients at the heart of drug development and access. ... Patients at the heart of drug development and access. If you believe the news every day, patients are becoming more and more involved in drug development

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. “ ... After a heart attack people tend to leave the hospital thinking the event is over.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics